Compare Sanofi SA (SNY) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Taskus Inc — how do they compare? Sanofi SA trades at $40.2 (market cap $96.81B), while Taskus Inc trades at $7.99 (market cap $723.41M). The key difference: Sanofi SA is far larger — about 133.8× Taskus Inc's market cap, and Sanofi SA pays a 6.02% dividend while Taskus Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Taskus Inc for 34 Days on average.
| SNY | TASK | |
|---|---|---|
Market Cap | $96.81B | $723.41M |
Volume | 2,081,815 | 201,303 |
Sector | Health | Technology |
52-Week High | $52.34 | $14.69 |
52-Week Low | $39.51 | $4.57 |
Typical Hold Time | 94 Days | 34 Days |
Enterprise Value | $116.20B | $1.09B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
TaskUs trades at $8.01, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expansion to 8.75%. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected, driven by AI services growth offsetting Trust & Safety declines.
The stock appears undervalued with P/E of 6.8 and P/S of 0.6, supported by analyst consensus target of $9.33 representing 16% upside. Key risks include labor cost pressures and client concentration, while AI segment growth at 26% provides upside catalyst. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
